Abstract
In addition to well-established genetic abnormalities -particularly gene mutations, deletions or translocations -, epigenetic abnormalities are also implicated in the development and progression of hematological malignancies. As such, the constitutive pattern of DNA methylation and histone acetylation observed in normal hematopoietic cells is remarkably altered in both myeloid and lymphoid tumors. Recent advances in the understanding of these transcriptional and post-transcriptional mechanisms in normal B and T cells as well as malignant lymphoid cells have been instrumental in the development of novel diagnostic markers, prognostic classification and targeted therapeutic approaches. This review focuses on the most important epigenetic alterations discovered in lymphoma-derived cell lines and primary lymphoid tumors and how pharmacologic manipulation of these abnormalities could eventually change the way we treat them in the clinic.
Keywords: DNA methylation, Histone acetylation, Demethylating agents, Histone deacetylase inhibitors, Non-Hodgkin's lymphoma, Hodgkin's lymphoma, Chronic lymphocytic leukemia
Current Cancer Drug Targets
Title: Novel Epigenetic Targets in Lymphoproliferative Disorders
Volume: 8 Issue: 5
Author(s): Julio Delgado
Affiliation:
Keywords: DNA methylation, Histone acetylation, Demethylating agents, Histone deacetylase inhibitors, Non-Hodgkin's lymphoma, Hodgkin's lymphoma, Chronic lymphocytic leukemia
Abstract: In addition to well-established genetic abnormalities -particularly gene mutations, deletions or translocations -, epigenetic abnormalities are also implicated in the development and progression of hematological malignancies. As such, the constitutive pattern of DNA methylation and histone acetylation observed in normal hematopoietic cells is remarkably altered in both myeloid and lymphoid tumors. Recent advances in the understanding of these transcriptional and post-transcriptional mechanisms in normal B and T cells as well as malignant lymphoid cells have been instrumental in the development of novel diagnostic markers, prognostic classification and targeted therapeutic approaches. This review focuses on the most important epigenetic alterations discovered in lymphoma-derived cell lines and primary lymphoid tumors and how pharmacologic manipulation of these abnormalities could eventually change the way we treat them in the clinic.
Export Options
About this article
Cite this article as:
Delgado Julio, Novel Epigenetic Targets in Lymphoproliferative Disorders, Current Cancer Drug Targets 2008; 8 (5) . https://dx.doi.org/10.2174/156800908785133222
DOI https://dx.doi.org/10.2174/156800908785133222 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Insights into the Role of Fc Gamma Receptors (FcγRs) Genetic Variations in Monoclonal Antibody-Based Anti-Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Lipid Rafts and Fas/CD95 Signaling in Cancer Chemotherapy
Recent Patents on Anti-Cancer Drug Discovery In-Situ Hybridization as a Molecular Tool in Cancer Diagnosis and Treatment
Current Medicinal Chemistry <i>In vivo</i> Anticancer Potential of Hydroxamic Acid Derivatives
Current Topics in Medicinal Chemistry Pancreatic Cancer and Personalized Medicine: Can Genomics Facilitate Early Diagnosis or Improve Therapeutic Outcomes?
Current Pharmacogenomics and Personalized Medicine The Anti-Cancer Activity of Noscapine: A Review
Recent Patents on Anti-Cancer Drug Discovery Immunotherapy of Kidney Cancer
Current Clinical Pharmacology Structure of Multidrug-Resistance Proteins of the ATP-Binding Cassette (ABC) Superfamily
Current Medicinal Chemistry - Anti-Cancer Agents Polymer Drug Conjugates: Recent Advancements in Various Diseases
Current Pharmaceutical Design Efalizumab
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry P-Glycoprotein and Breast Cancer Resistance Protein Affect Disposition of Tandutinib, A Tyrosine Kinase Inhibitor
Drug Metabolism Letters Redox-active and Redox-silent Compounds: Synergistic Therapeutics in Cancer
Current Medicinal Chemistry Aurora-B Kinase Inhibitors for Cancer Chemotherapy
Mini-Reviews in Medicinal Chemistry Insertional Mutagenesis by Retroviral Vectors: Current Concepts and Methods of Analysis
Current Gene Therapy Therapeutic Use of Brentuximab Vedotin in CD30+ Hematologic Malignancies
Anti-Cancer Agents in Medicinal Chemistry Haematopoietic Stem Cell Gene Therapy to Treat Autoimmune Disease
Current Stem Cell Research & Therapy Promotion of Insulin-Like Growth Factor-I Production by Sensory Neuron Stimulation; Molecular Mechanism(s) and Therapeutic Implications
Current Medicinal Chemistry Receptor Tyrosine Kinases: The Main Targets for New Anticancer Therapy
Current Drug Targets Developing Histone Deacetylase Inhibitors as Anti-Cancer Therapeutics
Current Medicinal Chemistry Turning Tumor-Promoting Copper into an Anti-Cancer Weapon via High-Throughput Chemistry
Current Medicinal Chemistry